Physiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH hamster model on June the 13th, 2022 at the Keystone Symposia “Tissue Fibrosis and Repair”, to be held in Keystone, Colorado, USA.

Meet Dr François Briand, our Director of Research and Development, during the Monday 13th poster session.

 Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.

About us

 Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.